10-Q: Heron Therapeutics Swings to Profit, Refinances Debt

Heron Therapeutics reported a net income for the first half of 2025, driven by strong acute care product sales and reduced operating expenses, while successfully refinancing its debt.

Summary

• Heron Therapeutics achieved a net income of $0.3 million for the six months ended June 30, 2025, a significant improvement from a net loss of $12.4 million in the same period of 2024.
• Operating income for the six months ended June 30, 2025, was $1.5 million, compared to an operating loss of $11.2 million in the prior year period.
• Total net product sales increased by 7.65% to $76.1 million for the six months ended June 30, 2025, up from $70.7 million in the comparable 2024 period.
• Acute care net product sales (ZYNRELEF and APONVIE) surged by 70.5% to $21.0 million for the six months ended June 30, 2025, primarily due to increased market share and new customers.
• Oncology net product sales (CINVANTI and SUSTOL) decreased by 5.6% to $55.1 million for the six months ended June 30, 2025, attributed to market competition from branded products and generics, a trend expected to continue.
• Gross profit margin improved to 75.9% for the six months ended June 30, 2025, compared to 73.2% in the prior year, driven by increased units sold and lower inventory reserves/write-offs.
• Operating expenses decreased by 10.6% to $56.3 million for the six months ended June 30, 2025, with notable reductions in research and development (42.3% decrease) and sales and marketing (4.7% decrease).
• The company successfully executed refinancing transactions on August 8, 2025, including a new Credit Facility of up to $150.0 million, issuance of $35.0 million in 5.0% senior convertible notes due 2031, and a $29.7 million equity raise through common and preferred stock.
• These refinancing transactions were used to retire the previous 1.5% senior convertible notes and the Working Capital Facility, providing additional working capital.
• Cash, cash equivalents, and short-term investments totaled $40.6 million as of June 30, 2025, down from $59.3 million at December 31, 2024.
• Net cash used in operating activities increased to $19.7 million for the six months ended June 30, 2025, from $14.1 million in the prior year, primarily due to higher inventory payments.

Sentiment

Score: 7

Explanation: The company demonstrated a significant financial turnaround to profitability and successfully refinanced its debt, addressing immediate liquidity concerns. Strong growth in acute care sales is a positive. However, declining oncology sales due to competition and ongoing patent litigations with other generic players introduce notable future uncertainties and risks to key product revenues.

Positives

• Achieved net income of $0.3 million for the six months ended June 30, 2025, a significant turnaround from a $12.4 million net loss in the prior year.
• Generated income from operations of $1.5 million for the six months ended June 30, 2025, reversing an $11.2 million operating loss from the previous year.
• Acute care product sales (ZYNRELEF and APONVIE) demonstrated robust growth, increasing by 70.5% for the six months ended June 30, 2025, driven by market share gains and new customers.
• Improved gross profit margin to 75.9% for the six months ended June 30, 2025, indicating better cost management and product profitability.
• Successfully completed comprehensive refinancing transactions, securing new debt and equity capital to address upcoming maturities and bolster working capital.
• Settled patent litigation with Mylan for generic versions of CINVANTI and APONVIE, establishing a clear generic entry date of June 1, 2032, for these products.
• ZYNRELEF received continued separate Medicare reimbursement in both hospital outpatient department and ambulatory surgical center settings from January 1, 2025, through December 31, 2027, enhancing market access.

Negatives

• Oncology net product sales (CINVANTI and SUSTOL) declined by 5.6% for the six months ended June 30, 2025, due to increased market competition from branded and generic products, a trend expected to persist.
• Net cash used in operating activities increased to $19.7 million for the six months ended June 30, 2025, compared to $14.1 million in the prior year, indicating higher cash burn from operations.
• Cash, cash equivalents, and short-term investments decreased to $40.6 million as of June 30, 2025, from $59.3 million at December 31, 2024.
• The company continues to carry a substantial accumulated deficit of $1.9 billion as of June 30, 2025.
• Ongoing patent litigations with Slayback and Qilu regarding generic versions of CINVANTI and APONVIE pose a risk of earlier generic entry than the Mylan settlement, with trials scheduled for November 2025 and November 2026 respectively.

Risks

• Reliance on single vendors for certain critical materials and components used in manufacturing products, which could lead to supply interruptions and increased costs.
• Exposure to geopolitical risks, including natural disasters, acts of war, terrorism, civil disorder, tariffs, and trade protection measures, which could disrupt global supply chains.
• Changes in government policies, laws, and regulations, including operational changes at regulatory agencies like the FDA and CMS, could negatively impact business operations and regulatory approvals.
• Inability to maintain satisfactory pricing and obtain adequate reimbursement from government and third-party payors for products, which could adversely affect revenue and profitability.
• Intense market competition from branded products and generics, particularly impacting oncology product sales, which is expected to continue.
• Potential adverse effects from changes to existing tax laws or challenges to current tax positions, such as the capitalization and amortization requirements for research and development expenditures.
• The Inflation Reduction Act of 2022 (IRA) and other healthcare reform measures could lead to lower revenues, increased downward pressure on drug prices, and impact profitability if products become subject to price negotiations.

Future Outlook

Management believes that existing cash, cash equivalents, and short-term investments, following the August 2025 refinancing transactions, will be sufficient to meet anticipated cash requirements for at least one year from the filing's issuance date. The company expects continued market competition and decreases in oncology net product sales for the foreseeable future. ZYNRELEF is included in a new Medicare payment methodology from January 1, 2025, through December 31, 2027, which may improve access but also lead to greater competition. The company intends to vigorously enforce its intellectual property rights related to CINVANTI and APONVIE amidst ongoing generic challenges.

Management Comments

• Management believes that existing cash, cash equivalents, and short-term investments will be sufficient to meet anticipated cash requirements for a period of at least one year from the date that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q are issued, based on current operating plan and projections and subsequent to the closing of the Refinancing Transactions.
• The decreases in oncology net product sales were primarily attributable to market competition from branded products and generics, and this competition and decreases are expected to continue for the foreseeable future.
• The company intends to vigorously enforce its intellectual property rights relating to CINVANTI and APONVIE.

Industry Context

The biotechnology and pharmaceutical industry is characterized by high R&D costs, intense competition, and significant regulatory and reimbursement pressures. Heron's acute care products, particularly ZYNRELEF, are benefiting from policy changes like the NOPAIN Act, which encourages non-opioid pain management. However, the oncology segment faces increasing generic competition, a common trend as patents expire. The broader economic and geopolitical environment, including tariffs and healthcare reform initiatives like the IRA, continues to impact drug pricing and supply chains across the industry.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results for direct industry standard assessment beyond general market competition.

Management Changes

Corporate Governance

Legal Proceedings

• Settled patent infringement litigation with Mylan Pharmaceuticals Inc. regarding generic CINVANTI, granting Mylan a license to market a generic version in the U.S. beginning June 1, 2032.
• Settled patent infringement litigation with Mylan Pharmaceuticals Inc. regarding generic APONVIE, granting Mylan a license to market a generic version in the U.S. beginning June 1, 2032.
• Ongoing patent infringement litigation against Slayback Pharma LLC (now Azurity Pharmaceuticals, Inc.) concerning generic CINVANTI, with a four-day bench trial scheduled for November 17, 2025. FDA approval for Slayback's NDA may be delayed until June 12, 2026, or resolution of litigation.
• Ongoing patent infringement litigation against Qilu Pharmaceutical (Hainan) Co., Ltd and Qilu Pharma, Inc. regarding generic APONVIE, with FDA approval potentially delayed until August 7, 2027, or resolution of litigation.
• Ongoing patent infringement litigation against Qilu Pharmaceutical (Hainan) Co., Ltd and Qilu Pharma, Inc. regarding generic CINVANTI, with FDA approval potentially delayed until December 11, 2027, or resolution of litigation.
• The Qilu CINVANTI and APONVIE litigations were consolidated on July 15, 2025, with a five-day bench trial currently scheduled for November 16, 2026.

Related Party Transactions

• The Senior Unsecured Convertible Notes were issued to funds affiliated with Baker Bros. Advisors LP in May 2021. While not explicitly detailed as a new transaction in this filing, the refinancing transactions involved the retirement of these notes, indicating a continued relationship with a significant investor group.

Stakeholder Impact

• **Shareholders**: Positive impact from the company's return to net income and successful debt refinancing, which reduces immediate financial risk. However, potential dilution from new stock issuance and ongoing generic competition for oncology products could create future headwinds.
• **Employees**: The Management Retention Agreement for Mark Hensley indicates efforts to retain key personnel, potentially boosting employee morale and stability. Reductions in personnel costs in R&D and Sales & Marketing suggest some workforce adjustments.
• **Customers (Healthcare Providers/Hospitals)**: Increased availability and market access for ZYNRELEF due to Medicare reimbursement changes. Continued availability of CINVANTI and APONVIE, though future generic competition could offer more options.
• **Creditors**: The refinancing transactions significantly alter the debt structure, retiring older notes and establishing new terms, which should provide greater clarity and stability for lenders.
• **Suppliers**: Continued reliance on single vendors for critical manufacturing components poses a risk to supply chain stability, which could impact the company's ability to produce and deliver products.

Next Steps

• Continue commercialization, marketing, and achieving market acceptance of ZYNRELEF, APONVIE, CINVANTI, and SUSTOL in the U.S.
• Successfully launch the ZYNRELEF Vial Access Needle (VAN) in the U.S.
• Develop, acquire, and advance product candidates into and successfully complete clinical trials.
• Submit for and obtain regulatory approval for product candidates.
• Meet postmarketing study requirements within mandated FDA timelines and comply with standard postmarketing requirements.
• Vigorously enforce intellectual property rights relating to CINVANTI and APONVIE in ongoing litigations with Slayback and Qilu.
• Prepare for the four-day bench trial scheduled for November 17, 2025, in the Slayback patent infringement case.
• Prepare for the five-day bench trial scheduled for November 16, 2026, in the consolidated Qilu CINVANTI and APONVIE litigations.

Key Dates

Recommendation

Heron Therapeutics has shown a commendable turnaround to profitability in the first half of 2025, driven by strong acute care product growth and effective cost management. The successful refinancing of significant debt obligations also alleviates immediate liquidity concerns. However, the oncology segment continues to face declining sales due to intense generic competition, a trend expected to persist. Furthermore, while the Mylan patent litigations are settled, ongoing and consolidated patent challenges from Slayback and Qilu for CINVANTI and APONVIE introduce substantial uncertainty regarding future revenue streams for these key products, with potential generic entry dates much earlier than the Mylan settlement. The recent capital raise, while necessary, also involves equity dilution. Given the mixed performance across segments and the significant legal overhang, a 'hold' recommendation is appropriate, balancing the recent positive financial momentum and debt resolution against the persistent competitive and legal challenges.

Keywords

Biotechnology, Pharmaceuticals, SEC Filing, 10-Q, Heron Therapeutics, HRTX, ZYNRELEF, APONVIE, CINVANTI, SUSTOL, Postoperative Pain, Nausea and Vomiting, Oncology, Acute Care, Financial Results, Patent Litigation, Debt Refinancing, Commercialization, Drug Delivery, Biochronomer Technology